Interferon alpha (IFNalpha) and psychiatric syndromes: a review (Q34790180)

4 August 2017

1 reference

title

Interferon alpha (IFNalpha) and psychiatric syndromes: a review (English)

1 reference

4 August 2017

8

Klaus Lieb

1 reference

4 August 2017

Heinz Grunze

7

0 references

Bernd L Fiebich

4

object named as

Bernd L Fiebich

1 reference

4 August 2017

Martin Schaefer

1

1 reference

4 August 2017

Marc A Engelbrecht

2

1 reference

4 August 2017

Oliver Gut

3

1 reference

4 August 2017

Joachim Bauer

5

1 reference

4 August 2017

Folkhard Schmidt

6

1 reference

4 August 2017

publication date

1 May 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

4 August 2017

published in

1 reference

4 August 2017

volume

26

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

731-746

1 reference

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Serum Interferon in First Psychotic Attack

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Alpha-interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon enhances the excitability of cultured neurones

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Cytokine-induced sickness behavior: where do we stand?

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Side effects of α interferon in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Successful treatment of interferon alfa-induced mood disorder with nortriptyline

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Neurological effects of recombinant human interferon.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon responses in schizophrenia and major depressive disorders

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Seizures associated with low-dose alpha-interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Prefrontal cortical hypometabolism during low-dose interferon alpha treatment

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression--a study with single photon emission computed tomography

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Cytokines and the brain: implications for clinical psychiatry

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Short and long term immunosuppressive effects of clozapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

[Systemic immunologic diseases as differential diagnosis in psychiatry]

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Effects of IFN-beta on human cerebral blood flow distribution

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Enhancement of immobility in mouse forced swimming test by treatment with human interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

The first case of polymyositis associated with interferon therapy

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Excitatory amino acid neurotoxicity and neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

The effect of interferon-alpha on the pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Persistent neurotoxicity of systemically administered interferon-alpha

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Naloxone blocks the interferon-alpha induced changes in hypothalamic neuronal activity

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Side effect profile of interferon beta-1b in MS: results of an open label trial

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Behavioral assessment of patients treated with alpha-interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Side effects of high-dose interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Reversible cognitive decline during high-dose alpha-interferon treatment.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Serum interferon in patients with psychosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Cytokine-associated emotional and cognitive disturbances in humans

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Interferon decreases REM latency

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Psychiatric complications of long-term interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Central nervous system toxicity of interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

1 reference

7 January 2021

Interferon-alpha in lupus psychosis

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Neurological effects of recombinant human interferon

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

The interaction between cytokines and neurotransmitters in depression and stress: possible mechanism of antidepressant treatments

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Manic episodes in two patients treated with interferon alpha

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Successful Treatment of Interferon-α-Induced Mood Disorder With Nortriptyline

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Treatment of Neurotoxic Side Effects of Interferon-α with Naltrexone

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Immunopathology and viral reactivation. A general theory of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Hepatitis C and depression

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Illness, cytokines, and depression

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

Serum interferon levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016/S0278-5846(01)00324-4

7 January 2021

10.1016/S0278-5846(01)00324-4

Identifiers

DOI

1 reference

4 August 2017

1 reference